Keywords

• According to Lu imatinib;2-Propen-1-one, 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-;(R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo-[3,4-d]pyrimidin-1-y
• PCI-32765;1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one;PCI-32765 (Ibrutinib);
• (R)-1-(3-(4-aMino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyriMidin-1-yl)piperidin-1-yl)prop-2-en-1-one;1-[(3R)-3-[4-AMino-3-(4-phenoxyphenyl)pyrazolo[3, 4-d]pyriMidin-1-yl]piperidin-1-yl]prop-2-en-1-on

Quick Details

• ProName: Ibrutinib
• CasNo: 936563-96-1
• Molecular Formula: C25H24N6O2
• Application: pharmaceutical intermediate
• PackAge: according to client's requirments
• Port: Shanghai,Tianjin, Qingdao
• ProductionCapacity: Metric Ton/Day
• Purity: 99%
• Transportation: BY AIR, BY SEA
• LimitNum: 1 Metric Ton

Superiority

Searchingredient.com concentrates on building a global leading search engine for ingredients in food, feed and pharmaceutical industry, thanks to its strong backgrounds in food, beverage and pharmaceutical raw material business. Buyers may get precise quotations for almost any food and feed ingredients, active pharmaceutical ingredients and relevant chemical reagents within 24 hours online at zero cost, as searchingredient.com has developed close ties with more than 100,000 certified suppliers worldwide over the past years, and a reliable inquiry tracking team and system. Searchingredient.com product database covers more than 20,000 food ingredients, active pharmaceutical ingredients and relevant chemical reagents, forming a professional reference book and dictionary of the industry, its high-standard chemical information data ranging from CAS No., EC No., molecular formula, molecular weight, product description, product synonyms to molecular structure. In the meantime, searchingredient.com owns a professional editorial team with international perspective, which focuses on collection of all sorts of industry information and provides industry news, market development tracking, in-depth analysis report and business review for suppliers, manufacturers, traders and purchasing agents from the food, feed and active pharmaceutical ingredients industry worldwide.

Details

Ibrutinib Usage And Synthesis Bruton tyrosine kinase (BTK) inhibitor Ibrutinib is a kind of Bruton tyrosine kinase (BTK) inhibitor, it could be used for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). MCL and CLL are belonged to the B-cell non-Hodgkin's lymphoma, which is difficult to cure and easy to recurrent. Common chemical immunotherapy does not have the targeting, often occurs 3 or 4 adverse reactions. Ibrutinib and B lymphocytes could target with BTK which is necessary for formation, differentiation, and transmission of information, inhibit BTK activity irreversibly, and inhibit tumor cell proliferation and survival effectively. Ibrutinib could be rapidly absorbed after oral administration, during 1~2h reach maximum blood concentration, adverse reactions belong to one or two, therefore, Ibrutinib will become a new choice of treatment of CLL and MCL. Food and Drug Administration (FDA) of USA has speed up approval of Pharmacyclics Corporation and Johnson & Johnson's Imbruvica (generic name: Ibrutinib) came to market to the cure a kind of rarely aggressive leukemia-mantle cell lymphoma (MCL) in 13th November, 2013. Ibrutinib is a new kind of oral Bruton tyrosine kinase (BTK) inhibitor, it was awarded by FDA be a breakthrough drugs in February of 2013, and approved the MCL and CLL treatments in 13th November, 2013 and 12th February, 2014 respectively. It could covalently bound selectively with cysteine residues (Cys-481) in active site of Btk target protein, irreversible inhibit BTK, thereby effectively prevent tumor cells from migrating from B cell to lymphoid tissue where adapt for tumor growth. Information was collated by Xiaonan editor of Chemicalbook.